Stanford researchers have found a way to reverse cartilage damage in aging joints by blocking a single protein — one that becomes more abundant as we get older. In older mice, an injection of a 15-PGDH inhibitor didn't just ease arthritis symptoms; it rebuilt worn cartilage and prevented osteoarthritis from developing after injuries similar to ACL tears.
Osteoarthritis affects roughly one in five American adults and costs the healthcare system about $65 billion annually. Most treatments manage pain without addressing what's actually happening inside the joint: cartilage wearing away and the inflammatory cascade that follows injury. This approach is different. It targets the root cause.
The protein 15-PGDH increases with age, and when researchers blocked it, something unexpected happened. The existing cartilage cells in the joint — chondrocytes — essentially reprogrammed themselves. Rather than degrading cartilage, they started building it. Cells that had been expressing genes tied to cartilage breakdown switched to expressing genes for healthy cartilage formation. No stem cells needed. Just the cells that were already there, redirected.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxA Shift in How We Think About Healing
When the team tested this on human cartilage tissue from osteoarthritis patients, the cells responded the same way. "The mechanism is quite striking," said co-senior author Nidhi Bhutani. "A large pool of already existing cells in cartilage are changing their gene expression patterns. By targeting these cells for regeneration, we may have an opportunity to have a bigger overall impact clinically."
The dramatic part: the cartilage regeneration in the older mice exceeded what any other drug or intervention has produced in research to date. And the same inhibitor has already been tested in humans for treating age-related muscle weakness, so researchers have safety data to build on.
Clinical trials for cartilage regeneration are expected to launch soon. If this works in humans the way it works in mice, the implications are significant — not just for people dealing with arthritis, but for anyone facing the slow wear of aging joints.
